Trials / Recruiting
RecruitingNCT06827899
Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML
A Multicenter, Prospective, Single-arm Clinical Study of Veneclax, Chidaniline Combined With Azacitidine (VCA) Followed by Decitabine + MAG Regimen (D-MAG) in the Treatment of Elderly Untreated Acute Myeloid Leukemia (AML)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)
Detailed description
A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) | Specified dose on specified days |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2026-06-30
- Completion
- 2027-06-30
- First posted
- 2025-02-14
- Last updated
- 2025-02-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06827899. Inclusion in this directory is not an endorsement.